Drugs / funobactam
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04802863 | Mar → May 2021 | bacterial infectious disease | Evopoint Biosciences Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | funobactam | “Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases.” PMID 42294651 ↗ Jun 2026 |
| Known as | XNW4107 | “Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases.” PMID 42294651 ↗ Jun 2026 |
| Action | Inhibit | “Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases.” PMID 42294651 ↗ Jun 2026 |
| Modality | Small molecule | — CHEMBL5095101 ↗ |
| Route | Intravenous | “Twenty participants received a 60 min intravenous infusion of imipenem 500 mg/cilastatin 500 mg combined with funobactam 250 mg every 6 h for five doses.” PMID 42294651 ↗ Jun 2026 |